Back to Authors

Litzow, Mark R.

https://orcid.org/0000-0002-9816-6302

A5085360755 | I1330342723

Mayo Clinic

Citations 731

Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3945-3946

10.1182/blood-2022-160179

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10447-10448

10.1182/blood-2022-169266

Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8921-8922

10.1182/blood-2022-165446

Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6285-6287

10.1182/blood-2022-170587

Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6058-6060

10.1182/blood-2022-163795

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9057-9060

10.1182/blood-2022-169307

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9675-9676

10.1182/blood-2022-163485

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12353-12354

10.1182/blood-2022-155561

Comparison of Allogeneic Hematopoietic Cell Transplantation Outcomes from Younger Matched Unrelated Donor Versus Older Sibling Donor for Acute Myeloid Leukemia

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 909-910

10.1182/blood-2022-162742

Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6187-6188

10.1182/blood-2022-170647